Lyell Immunopharma
LYEL
79 hedge funds and large institutions have $503M invested in Lyell Immunopharma in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 36 increasing their positions, 10 reducing their positions, and 15 closing their positions.
3,211% more call options, than puts
Call options by funds: $3.05M | Put options by funds: $92K
260% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 10
13% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 15
3% more funds holding
Funds holding: 77 → 79 (+2)
0.29% more ownership
Funds ownership: 1.78% → 2.07% (+0.29%)
24% less capital invested
Capital invested by funds: $662M → $503M (-$159M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.2M |
| 2 |
BlackRock
New York
|
+$35.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.92M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.6M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.42M |
Top Sellers
| 1 |
SM
SB Management
Abu Dhabi,
United Arab Emirates
|
-$27.1M |
| 2 |
E
Ergoteles
New York
|
-$7.8M |
| 3 |
Brown Advisory
Baltimore,
Maryland
|
-$4.18M |
| 4 |
Morgan Stanley
New York
|
-$3.9M |
| 5 |
HF
HRT Financial
New York
|
-$1.72M |
LYEL Hedge Fund Activity: Q1 2022 in Review
79 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Lyell Immunopharma (LYEL) for Q1 2022, worth a combined $503M — down 24% from $662M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new LYEL positions and 15 closed out — a net gain of 2 holders — while 36 added to existing stakes and 10 trimmed.
The largest buyer was Vanguard Group, adding an estimated $40.2M. The largest seller was SB Management, exiting entirely with an estimated $27.1M sold.
- 79 institutional investors held Lyell Immunopharma (LYEL) as of Q1 2022, up from 77 in Q4 2021.
- Funds reported $503M of Lyell Immunopharma stock for Q1 2022, down 24% quarter-over-quarter.
- 17 funds opened new Lyell Immunopharma positions in Q1 2022 and 15 closed out, a net change of +2 holders.
- The largest Lyell Immunopharma buyer in Q1 2022 was Vanguard Group, an estimated $40.2M added.
- The largest Lyell Immunopharma seller in Q1 2022 was SB Management, an estimated $27.1M sold.
Based on aggregated 13F filings for Q1 2022.